Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 337

1.

Consequences of interleukin 1β-triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4+ infiltration mimics human proliferative inflammatory atrophy.

Ashok A, Keener RA, Rubenstein M, Stookey S, Bajpai S, Hicks J, Alme AK, Drake CG, Zheng Q, Trabzonlu L, Yegnasubramanian S, De Marzo AM, Bieberich CJ.

Prostate. 2019 Mar 22. doi: 10.1002/pros.23784. [Epub ahead of print]

PMID:
30900284
2.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

3.

The Immunobiology of Kidney Cancer.

Drake CG, Stein MN.

J Clin Oncol. 2018 Oct 29:JCO2018792648. doi: 10.1200/JCO.2018.79.2648. [Epub ahead of print]

PMID:
30372396
4.

A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.

Yu SH, Maynard JP, Vaghasia AM, De Marzo AM, Drake CG, Sfanos KS.

Prostate. 2019 Feb;79(2):215-222. doi: 10.1002/pros.23726. Epub 2018 Oct 21.

PMID:
30345534
5.

Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation.

Le Magnen C, Virk RK, Dutta A, Kim JY, Panja S, Lopez-Bujanda ZA, Califano A, Drake CG, Mitrofanova A, Abate-Shen C.

Dis Model Mech. 2018 Nov 16;11(11). pii: dmm035139. doi: 10.1242/dmm.035139.

6.

Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.

Harris-Bookman S, Mathios D, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, Kim J, Taube JM, Burger PC, Selby M, Taitt C, Korman A, Ye X, Drake CG, Brem H, Pardoll DM, Lim M.

Int J Cancer. 2018 Dec 15;143(12):3201-3208. doi: 10.1002/ijc.31661. Epub 2018 Sep 24.

PMID:
30248181
7.

Immunotherapy for Prostate Cancer.

Venturini NJ, Drake CG.

Cold Spring Harb Perspect Med. 2018 Sep 10. pii: a030627. doi: 10.1101/cshperspect.a030627. [Epub ahead of print]

PMID:
30201787
8.

Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors.

Haffner MC, Taheri D, Luidy-Imada E, Palsgrove DN, Eich ML, Netto GJ, Matoso A, Nirschl TR, Zheng Q, Hicks JL, Nelson WG, De Marzo AM, Marchionni L, Drake CG, Yegnasubramanian S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8580-E8582. doi: 10.1073/pnas.1803292115. Epub 2018 Sep 4. No abstract available.

9.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4.

10.

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.

Comiskey MC, Dallos MC, Drake CG.

Curr Oncol Rep. 2018 Aug 18;20(9):75. doi: 10.1007/s11912-018-0712-z. Review.

PMID:
30120592
11.

Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization.

Barberi T, Martin A, Suresh R, Barakat DJ, Harris-Bookman S, Drake CG, Lim M, Friedman AD.

Cancer Immunol Immunother. 2018 Oct;67(10):1491-1503. doi: 10.1007/s00262-018-2184-2. Epub 2018 Jul 21.

PMID:
30030559
12.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

13.

IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy.

Chen JC, Perez-Lorenzo R, Saenger YM, Drake CG, Christiano AM.

Cell Syst. 2018 Jul 25;7(1):92-103.e4. doi: 10.1016/j.cels.2018.05.020. Epub 2018 Jun 27.

PMID:
29960886
14.

Systemic depletion of lymphocytes following focal radiation to the brain in a murine model.

Piotrowski AF, Nirschl TR, Velarde E, Blosser L, Ganguly S, Burns KH, Luznik L, Wong J, Drake CG, Grossman SA.

Oncoimmunology. 2018 May 9;7(7):e1445951. doi: 10.1080/2162402X.2018.1445951. eCollection 2018.

PMID:
29900062
15.

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG.

Clin Cancer Res. 2018 Oct 15;24(20):5058-5071. doi: 10.1158/1078-0432.CCR-17-3427. Epub 2018 Jun 13.

PMID:
29898992
16.

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.

Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG.

Clin Cancer Res. 2018 Oct 1;24(19):4662-4671. doi: 10.1158/1078-0432.CCR-18-0638. Epub 2018 Jun 1.

PMID:
29858218
17.

PD-L1 expression in medulloblastoma: an evaluation by subgroup.

Martin AM, Nirschl CJ, Polanczyk MJ, Bell WR, Nirschl TR, Harris-Bookman S, Phallen J, Hicks J, Martinez D, Ogurtsova A, Xu H, Sullivan LM, Meeker AK, Raabe EH, Cohen KJ, Eberhart CG, Burger PC, Santi M, Taube JM, Pardoll DM, Drake CG, Lim M.

Oncotarget. 2018 Apr 10;9(27):19177-19191. doi: 10.18632/oncotarget.24951. eCollection 2018 Apr 10.

18.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

PMID:
29577933
19.

Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.

Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, Miller R, Nugent K, Shinder B, Tosoian J, Fuchs EJ, Tran PT, Hurley PJ, Vuica-Ross M, Schaeffer EM, Drake CG, Ross AE.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):126-136. doi: 10.1038/s41391-018-0035-z. Epub 2018 Mar 20.

PMID:
29556048
20.

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.

Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG.

Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22.

21.

Quantitative Analysis of Immune Infiltrates in Primary Melanoma.

Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM.

Cancer Immunol Res. 2018 Apr;6(4):481-493. doi: 10.1158/2326-6066.CIR-17-0360. Epub 2018 Feb 21.

PMID:
29467127
22.

Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.

Dallos MC, Drake CG.

Cancer J. 2018 Jan/Feb;24(1):20-30. doi: 10.1097/PPO.0000000000000302. Review.

PMID:
29360724
23.

Inhibitors of the PD-1 Pathway in Tumor Therapy.

LaFleur MW, Muroyama Y, Drake CG, Sharpe AH.

J Immunol. 2018 Jan 15;200(2):375-383. doi: 10.4049/jimmunol.1701044. Review.

24.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, Choueiri TK, Van Allen EM.

Science. 2018 Feb 16;359(6377):801-806. doi: 10.1126/science.aan5951. Epub 2018 Jan 4.

25.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

26.

Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.

Shen YC, Ghasemzadeh A, Kochel CM, Nirschl TR, Francica BJ, Lopez-Bujanda ZA, Carrera Haro MA, Tam A, Anders RA, Selby MJ, Korman AJ, Drake CG.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):113-125. doi: 10.1038/s41391-017-0013-x. Epub 2017 Dec 4.

27.

Biomarkers for immunotherapy in bladder cancer: a moving target.

Aggen DH, Drake CG.

J Immunother Cancer. 2017 Nov 21;5(1):94. doi: 10.1186/s40425-017-0299-1. Review.

28.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA.

Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7.

29.

Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG.

Cancer Immunol Res. 2017 Dec;5(12):1074-1085. doi: 10.1158/2326-6066.CIR-16-0390. Epub 2017 Oct 19.

30.

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.

Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, Carrera-Haro MA, Ghasemzadeh A, Marciscano AE, Velarde E, Tam AJ, Thoburn CJ, Uddin M, Meeker AK, Anders RA, Pardoll DM, Drake CG.

Cancer Immunol Res. 2017 Nov;5(11):992-1004. doi: 10.1158/2326-6066.CIR-17-0040. Epub 2017 Oct 2.

31.

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.

PMID:
28838209
32.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.

33.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

34.

The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.

Ball MW, Gorin MA, Drake CG, Hammers HJ, Allaf ME.

Eur Urol Focus. 2017 Dec;3(6):584-589. doi: 10.1016/j.euf.2017.01.007. Epub 2017 Feb 8.

35.

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.

Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, Cella D, Gupta RT, Bhatt R, Van Allen E, Lara P, Choueiri TK, Kapoor A, Heng DYC, Shuch B, Jewett M, George D, Michaelson D, Carducci MA, McDermott D, Allaf M.

Kidney Cancer. 2017 Jul 26;1(1):31-40. doi: 10.3233/KCA-170010. Review.

36.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

37.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

38.

Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.

Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ.

Cancer Immunol Res. 2017 Jul;5(7):594-603. doi: 10.1158/2326-6066.CIR-16-0267. Epub 2017 Jun 6.

39.

Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.

Lopez-Bujanda Z, Drake CG.

J Leukoc Biol. 2017 Aug;102(2):393-406. doi: 10.1189/jlb.5VMR1116-491RR. Epub 2017 May 26. Review.

PMID:
28550116
40.

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.

Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw261. Review.

41.

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer.

Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake CG.

Immunotargets Ther. 2017 Mar 20;6:11-16. doi: 10.2147/ITT.S122497. eCollection 2017.

42.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

43.

LAG3 (CD223) as a cancer immunotherapy target.

Andrews LP, Marciscano AE, Drake CG, Vignali DA.

Immunol Rev. 2017 Mar;276(1):80-96. doi: 10.1111/imr.12519. Review.

44.

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengeløv L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W.

J Clin Oncol. 2017 Jan;35(1):40-47. Epub 2016 Oct 31.

PMID:
28034081
45.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL.

J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016.

46.

Risk Associated With High-Dose Bicalutamide.

Drake CG.

J Clin Oncol. 2017 Feb;35(4):471. doi: 10.1200/JCO.2016.69.4299. Epub 2016 Nov 21. No abstract available.

PMID:
27870564
47.

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Danilova L, Wang H, Sunshine J, Kaunitz GJ, Cottrell TR, Xu H, Esandrio J, Anders RA, Cope L, Pardoll DM, Drake CG, Taube JM.

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. Epub 2016 Nov 11.

48.

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.

Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC, Chang NN, DeVries T, Sheikh NA, Drake CG; STAND Investigators.

Clin Cancer Res. 2017 May 15;23(10):2451-2459. doi: 10.1158/1078-0432.CCR-16-1780. Epub 2016 Nov 10.

49.

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.

Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M.

J Immunother Cancer. 2016 Nov 4;4:74. doi: 10.1186/s40425-016-0181-6. eCollection 2016.

50.

Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.

Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):28-35. doi: 10.1038/pcan.2016.49. Epub 2016 Nov 1.

PMID:
27801901

Supplemental Content

Loading ...
Support Center